N-isopropyl-3-(pyridin-2-yl)-1-trityl-1H-pyrazolo[4,3-c]pyridin-4-amine | 1459257-79-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N-isopropyl-3-(pyridin-2-yl)-1-trityl-1H-pyrazolo[4,3-c]pyridin-4-amine
• 英文别名: N-propan-2-yl-3-pyridin-2-yl-1-tritylpyrazolo[4,3-c]pyridin-4-amine
• CAS: 1459257-79-4
• 化学式: C₃₃H₂₉N₅
• 分子量: 495.627
• InChiKey: SBJUHFSCCCRPAY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-isopropyl-3-(pyridin-2-yl)-1-trityl-1H-pyrazolo[4,3-c]pyridin-4-amine 在 三乙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以54%的产率得到N-isopropyl-3-(pyridin-2-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine
  参考文献：
  名称：

  PYRAZOLOPYRIDINE COMPOUNDS

  摘要：

  该发明的第一个方面涉及公式（1A）或（1B）的化合物，或其药用盐，其中R1是从烷基、单环杂环烷基、双环杂环烷基和环烷基中选择的基团，每个基团可以选择性地被取代，X1、X2、X3和X4的定义如本文所述。进一步方面涉及制药组合物、治疗用途和制备公式（1A）和（1B）化合物的过程。

  公开号：

  US20140288043A1
• 作为产物：
  描述：

  4-chloro-3-iodo-1-trityl-1H-pyrazolo[4,3-c]pyridine 在 copper(l) iodide 、 四(三苯基膦)钯 、 trans-bis(triphenylphosphine)palladium dichloride 、 N,N-二异丙基乙胺 、 lithium chloride 作用下， 以 四氢呋喃 、 甲苯 、 正丁醇 为溶剂， 反应 3.5h， 生成 N-isopropyl-3-(pyridin-2-yl)-1-trityl-1H-pyrazolo[4,3-c]pyridin-4-amine
  参考文献：
  名称：

  PYRAZOLOPYRIDINE COMPOUNDS

  摘要：

  该发明的第一个方面涉及公式（1A）或（1B）的化合物，或其药用盐，其中R1是从烷基、单环杂环烷基、双环杂环烷基和环烷基中选择的基团，每个基团可以选择性地被取代，X1、X2、X3和X4的定义如本文所述。进一步方面涉及制药组合物、治疗用途和制备公式（1A）和（1B）化合物的过程。

  公开号：

  US20140288043A1

文献信息

• [EN] PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2<br/>[FR] PYRAZOLOPYRIDINES EN TANT QU'INHIBITEURS DE LA KINASE LRRK2
  申请人：MEDICAL RES COUNCIL TECHNOLOGY

  公开号：WO2011141756A1

  公开（公告）日：2011-11-17

  A compound of formula la or formula lb, or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from: aryl; heteroaryl; -NHR3; fused aryl-C4-7-heterocycloalkyl; - CONR4R5; -NHCOR6; -C3-7-cycloalkyl; -0-C3-7-cycloalkyl; -NR3R6; and optionally substituted -C1-6 alkyl; wherein said aryl, heteroaryl, fused aryl-C4-7-heterocycloalkyl and C4-7- heterocycloalkyl are each optionally substituted; Q is CN, halogen, or is selected from C1-6-alkyl, C3-7-cycloalkyl, heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted with one or more substituents A; R2 is selected from hydrogen, aryl, C1-6-alkyl, C2-6-alkenyl,C3-7-cycloalkyl, heteroaryl, C4-7 heterocycloalkyl and halogen, wherein said C1-6-alkyl,, Cz-B-alkenyl, aryl, heteroaryl and C4-7-heterocycloalkyl are each optionally substituted;R3 is selected from aryl, heteroaryl, C4-7-heterocycloalkyl, C3-7- cycloalkyl, fused aryl-C-heterocycloalkyl and C1-6-alkyl, each of which is optionally substituted; R4 and R5 are each independently hydrogen, or optionally substituted C3-7- cycloalkyl, aryl, heteroaryl, C1-6-alkyl or C3-6-heterocycloalkyl; or R4 and R5 together with the N to which they are attached form a C3-6-heterocycloalkyl ring; each R6 is independently selected from C1-6-alkyl, C3-7 cycloalkyl, C-heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; each R7 is selected from hydrogen, optionally substituted C1-6-alkyl and C3-7-cycloalkyl; each of R8 and R9 is independently hydrogen or optionally substituted C1-6-alkyl; or R8 and R9 together with the N to which they are attached form a C4-6-heterocycloalkyl; each R10 is selected from C3-7- cycloalkyl and optionally substituted C1-6-alkyl; each R11 is independently selected from C1-6-alkyl, C3-7-cycloalkyl, C1-6-alkyl-C3-7-cycloalkyl, C4-7-heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; A is selected from halogen, - NR4S02R5, -CN, -OR6, -NR4R5, -NR7R11, hydroxyl, -CF3, -CONR4R5, -NR4COR5, -NR7(CO)NR4R5, -N02, -C02H, -C02R6, -S02R6, -S02NR4R5, -NR4COR5 ,-NR4COOR5, 6-alkyl and -COR6. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formulae la and lb.

  一种具有化学式la或化学式lb的化合物，或其在药学上可接受的盐或酯，其中R1选择自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-0-C3-7-环烷基；-NR3R6；以及可选择地取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选择地取代；Q选择自CN、卤素，或选择自C1-6-烷基、C3-7-环烷基、杂环烷基、芳基和杂环芳基，每种均可选择地取代一个或多个取代基A；R2选择自氢、芳基、C1-6-烷基、C2-6-烯烃基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6-烷基、C2-6-烯烃基、芳基、杂环芳基和C4-7-杂环烷基均可选择地取代；R3选择自芳基、杂环芳基、C4-7-杂环烷基、C3-7-环烷基、融合芳基-C-杂环烷基和C1-6-烷基，每种均可选择地取代；R4和R5各自独立地为氢，或可选择地取代的C3-7-环烷基、芳基、杂环芳基、C1-6-烷基或C3-6-杂环烷基；或R4和R5与其连接的N一起形成一个C3-6-杂环烷基环；每个R6独立地选择自C1-6-烷基、C3-7-环烷基、C-杂环烷基、芳基和杂环芳基，每种均可选择地取代；每个R7选择自氢、可选择地取代的C1-6-烷基和C3-7-环烷基；每个R8和R9各自独立地为氢或可选择地取代的C1-6-烷基；或R8和R9与其连接的N一起形成一个C4-6-杂环烷基；每个R10选择自C3-7-环烷基和可选择地取代的C1-6-烷基；每个R11独立地选择自C1-6-烷基、C3-7-环烷基、C1-6-烷基-C3-7-环烷基、C4-7-杂环烷基、芳基和杂环芳基，每种均可选择地取代；A选择自卤素、-NR4S02R5、-CN、-OR6、-NR4R5、-NR7R11、羟基、-CF3、-CONR4R5、-NR4COR5、-NR7(CO)NR4R5、-N02、-C02H、-C02R6、-S02R6、-S02NR4R5、-NR4COR5、-NR4COOR5、6-烷基和-COR6。进一步涉及到具有化学式la和lb的化合物的制药组合物、治疗用途和制备过程。
• [EN] PYRAZOLOPYRIDINES FOR TREATMENT OF PARKINSONS DISEASE<br/>[FR] PYRAZOLOPYRIDINES POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013139882A1

  公开（公告）日：2013-09-26

  The invention relates to a compound of formula (1A) or (1B), or a pharmaceutically acceptable salt thereof, Wherein R1 is a group selected from alkyl, monocyclic heterocycloalkyl, bicyclic heterocycloalkyl and cycloalkyl, each of which is optionally substituted by one or more groups selected from alkyl, halo and cycloalkyl; for formula (1A): one, two or three of X1, X2, X3 and X4 are N, and the remainder are each independently CR2; or for formula (1B): X4 is C or N; and one or two of X1, X2and X3 are independently selected from N and NR8, and the remainder are each independently CR2; such that X1, X2,X3,X4and N form a heteroaryl group; each R2 is independently selected from H, alkyl, CN, halo, heteroaryl, heterocycloalkyl, cycloalkyl, OR4, CONR5R6 and SO2R7, wherein said alkyl, heteroaryl, heterocycloalkyl and cycloalkyl groups are each optionally further substituted by one or more groups selected from alkyl, halo and OR9; each R8 is independently selected from H and alkyl, wherein said alkyl group is optionally further substituted by one or more groups selected from CN, halo, heteroaryl, heterocycloalkyl, cycloalkyl, OR4, CONR5R6 and SO2R7; R4, R5, R6, R7and R9 are each independently selected from H and alkyl; or R5 and R6 together with the nitrogen to which they are attached are linked to form a cyclic group which optionally further comprises one or more heteroatoms selected from O, N and S; with the proviso that when the compound is of formula (IB), the compound is other than 3-(5-isopropyl-4H-1,2,4-triazol-3-yl)-N- (tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine or 3-(5-cyclopropyl-4H-,2,4-triazol-3-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[4,3-c]pyridin-4-amine. Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formula (1A) and (1B).

  该发明涉及公式（1A）或（1B）的化合物，或其药学上可接受的盐，其中R1是从烷基、单环杂环烷基、双环杂环烷基和环烷基中选择的基团，每个基团可选择性地被一个或多个来自烷基、卤素和环烷基的基团取代；对于公式（1A）：X1、X2、X3和X4中的一个、两个或三个为N，其余各自独立地为CR2；或对于公式（1B）：X4为C或N；X1、X2和X3中的一个或两个独立地从N和NR8中选择，其余各自独立地为CR2；使得X1、X2、X3、X4和N形成一个杂芳基团；每个R2独立地从H、烷基、CN、卤素、杂芳基、杂环烷基、环烷基、OR4、CONR5R6和SO2R7中选择，其中所述的烷基、杂芳基、杂环烷基和环烷基基团可进一步被一个或多个来自烷基、卤素和OR9的基团取代；每个R8独立地从H和烷基中选择，其中所述的烷基基团可进一步被一个或多个来自CN、卤素、杂芳基、杂环烷基、环烷基、OR4、CONR5R6和SO2R7的基团取代；R4、R5、R6、R7和R9各自独立地从H和烷基中选择；或R5和R6与它们连接的氮一起形成一个环状基团，该基团可选择性地进一步包含一个或多个来自O、N和S的杂原子；但是当化合物为公式（IB）时，化合物不是3-(5-异丙基-4H-1,2,4-三唑-3-基)-N-(四氢-2H-吡喃-4-基)-1H-吡唑并[4,3-c]吡啶-4-胺或3-(5-环丙基-4H-1,2,4-三唑-3-基)-N-(四氢-2H-吡喃-4-基)-1H-吡唑并[4,3-c]吡啶-4-胺。进一步涉及制备公式（1A）和（1B）化合物的药物组合物、治疗用途和工艺方面。
• PYRAZOLOPYRIDINES AS INHIBITORS OF THE KINASE LRRK2
  申请人：Chan Brayn

  公开号：US20130267513A1

  公开（公告）日：2013-10-10

  A compound of formula Ia or formula Ib, or a pharmaceutically acceptable salt or ester thereof, wherein R 1 is selected from: aryl; heteroaryl; —NHR 3 ; fused aryl-C 4-7 -heterocycloalkyl; —CONR 4 R 5 ; —NHCOR 6 ; —C 3-7 -cycloalkyl; -0-C 3-7 -cycloalkyl; —NR 3 R 6 ; and optionally substituted —C 1-6 alkyl; wherein said aryl, heteroaryl, fused aryl-C 4-7 -heterocycloalkyl and C 4-7 -heterocycloalkyl are each optionally substituted; Q is CN, halogen, or is selected from C 1-6 -alkyl, C 3-7 -cycloalkyl, heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted with one or more substituents A; R 2 is selected from hydrogen, aryl, C 1-6 -alkyl, C 2-6 -alkenyl, C 3-7 -cycloalkyl, heteroaryl, C 4-7 -heterocycloalkyl and halogen, wherein said C 1-6 -alkyl, Cz-B-alkenyl, aryl, heteroaryl and C 4-7 -heterocycloalkyl are each optionally substituted; R 3 is selected from aryl, heteroaryl, C 4-7 -heterocycloalkyl, C 3-7 -cycloalkyl, fused aryl-C-heterocycloalkyl and C 1-6 -alkyl, each of which is optionally substituted; R 4 and R 5 are each independently hydrogen, or optionally substituted C 3-7 -cycloalkyl, aryl, heteroaryl, C 1-6 -alkyl or C 3-6 -heterocycloalkyl; or R 4 and R 5 together with the N to which they are attached form a C 3-6 -heterocycloalkyl ring; each R 6 is independently selected from C 1-6 -alkyl, C 3-7 -cycloalkyl, C-heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; each R 7 is selected from hydrogen, optionally substituted C 1-6 -alkyl and C 3-7 -cycloalkyl; each of R 8 and R 9 is independently hydrogen or optionally substituted C 1-6 -alkyl; or R 8 and R 9 together with the N to which they are attached form a C 4-6 -heterocycloalkyl; each R 10 is selected from C 3-7 -cycloalkyl and optionally substituted C 1-6 -alkyl; each R 11 is independently selected from C 1-6 -alkyl, C 3-7 -cycloalkyl, C 1-6 -alkyl-C 3-7 -cycloalkyl, C 4-7 -heterocycloalkyl, aryl and heteroaryl, each of which is optionally substituted; A is selected from halogen, —NR 4 S0 2 R 5 , —CN, —OR 6 , —NR 4 R 5 , —NR 7 R 11 , hydroxyl, —CF 3 , —CONR 4 R 5 , —NR 4 COR 5 , —NR 7 (CO)NR 4 R 5 , —N0 2 , —C0 2 H, —C0 2 R 6 , —S0 2 R 6 , —S0 2 NR 4 R 5 , —NR 4 COR 5 , —NR 4 COOR 5 , 6 -alkyl and —COR 6 . Further aspects relate to pharmaceutical compositions, therapeutic uses and process for preparing compounds of formulae Ia and Ib.

  公式Ia或公式Ib的化合物，或其药学上可接受的盐或酯，其中R1选自：芳基；杂环芳基；-NHR3；融合芳基-C4-7-杂环烷基；-CONR4R5；-NHCOR6；-C3-7-环烷基；-0-C3-7-环烷基；-NR3R6；和可选取代的-C1-6烷基；其中所述的芳基、杂环芳基、融合芳基-C4-7-杂环烷基和C4-7-杂环烷基均可选取代基；Q为CN、卤素，或选自C1-6烷基、C3-7-环烷基、杂环烷基、芳基和杂环芳基，每种基均可选取代基A；R2选自氢、芳基、C1-6烷基、C2-6烯基、C3-7-环烷基、杂环芳基、C4-7-杂环烷基和卤素，其中所述的C1-6烷基、C2-6烯基、芳基、杂环芳基和C4-7-杂环烷基均可选取代基；R3选自芳基、杂环芳基、C4-7-杂环烷基、C3-7-环烷基、融合芳基-C-杂环烷基和C1-6烷基，每种基均可选取代基；R4和R5各自独立地为氢，或可选取代的C3-7-环烷基、芳基、杂环芳基、C1-6烷基或C3-6-杂环烷基；或R4和R5与它们连接的N一起形成C3-6-杂环烷基环；每个R6各自选自C1-6烷基、C3-7-环烷基、C-杂环烷基、芳基和杂环芳基，每种基均可选取代基；每个R7选自氢、可选取代的C1-6烷基和C3-7-环烷基；每个R8和R9各自独立地为氢或可选取代的C1-6烷基；或R8和R9与它们连接的N一起形成C4-6-杂环烷基；每个R10选自C3-7-环烷基和可选取代的C1-6烷基；每个R11各自独立地选自C1-6烷基、C3-7-环烷基、C1-6-烷基-C3-7-环烷基、C4-7-杂环烷基、芳基和杂环芳基，每种基均可选取代基；A选自卤素、-NR4S02R5、-CN、-OR6、-NR4R5、-NR7R11、羟基、-CF3、-CONR4R5、-NR4COR5、-NR7(CO)NR4R5、-N02、-C02H、-C02R6、-S02R6、-S02NR4R5、-NR4COR5、-NR4COOR5、6-烷基和-COR6。此外，还涉及公式Ia和Ib的化合物的制备过程、药物组合物和治疗用途。
• US8907091B2
  申请人：——

  公开号：US8907091B2

  公开（公告）日：2014-12-09